SK Pharmteco Launches Catalyst Kit to Accelerate Continuous…

Event summary

SK Pharmteco launched the Catalyst Kit on September 24, 2026, a structured program for catalytic reaction development and continuous manufacturing scale-up.
The kit provides 12 catalysts (10 g samples each) and a three-stage development pathway: Screen to Identify, Optimize to Perform, and Scale with Confidence.
The program combines catalyst manufacturing with continuous fixed-bed reactor (FBR) technology for high-pressure, high-temperature reactions.
SK Pharmteco claims continuous catalytic flow processes offer cost savings, enhanced safety, sustainability, and predictable scale-up compared to batch processing.

The big picture

SK Pharmteco's Catalyst Kit targets the growing industry shift towards continuous manufacturing, which offers efficiency, safety, and sustainability advantages over traditional batch processing. The launch aligns with broader trends in pharmaceutical manufacturing towards more streamlined, scalable, and environmentally friendly production methods. The company's deep technical expertise and global presence position it to capture a significant share of the market for catalytic reaction development and continuous manufacturing solutions.

What we're watching

Adoption Pace: How quickly pharmaceutical and biotech innovators will adopt the Catalyst Kit for their catalytic reaction development needs.
Competitive Response: Whether competitors will introduce similar structured programs to streamline catalytic reaction development and continuous manufacturing.
Scale-Up Success: The pace at which optimized process conditions will be successfully transferred from lab scale to full-scale GMP commercial manufacturing.